{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/331823921"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs, and SSRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, he" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "nih.gov" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/316146645"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/331823921" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/512710455"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/331823921" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/867802"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/331823921"] } } }
